GenePhit
The GenePHIT trial is a Phase II clinical trial evaluating the safety and efficacy of AB-1002, a gene therapy for congestive heart failure (CHF). This trial aims to help patients with non-ischemic cardiomyopathy and NYHA Class III heart failure symptoms who are not adequately treated with standard medications. The gene therapy involves a single intracoronary infusion of AB-1002 and is being studied in a randomized, double-blind, placebo-controlled study.
Golden Halo
Researchers in Iowa are investigating new approaches, such as immunotherapy and targeted therapies, to improve patient outcomes. The state's commitment to brain cancer research positions it as a crucial player in the global fight against this disease.
Psilocybin vs Ketamine-Assisted Psychotherapy and Cardiometabolic Outcomes
This clinical trial aims to compare the effects of psilocybin-assisted psychotherapy (PAP) and ketamine-assisted psychotherapy (KAP) on cardiometabolic health. The study will assess changes in biomarkers like blood pressure, cholesterol, and insulin resistance in participants with treatment-resistant depression. By comparing the two interventions, researchers hope to gain insights into their potential impact on physical health and identify the most effective treatment for improving both mental and physical well-being.